Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Scientists have discovered an enzyme in the "developmental pathway" of patients with embryonal tumors within multilayers rosettes - an uncommon but deadly childhood brain cancer - which they say may lead to more effective treatment of the disease.
The study, published in the journal Nature Genetics, was led by researchers from the Research Institute of the McGill University Health Centre (RI-MUHC), the McGill University and Génome Québec Innovation Centre and The Hospital for Sick Children (SickKids) in Canada.
According to the researchers, the brain cancer embryonal tumors within multilayers rosettes (ETMRs), also known as embryonal tumors with abundant neuropil and true rosettes (ETANTR), is only found in children under the age of four.
The investigators note that although the cancer is rare, it is almost always fatal, even though treatment for it is aggressive.
With this in mind, the researchers looked to determine what the driver was behind ETMR/ETANTR tumor growth.
They analyzed five large public data sets looking at patients with ETMR/ETANTR and created "genomic" profiles of the tumors.
From this, it was discovered that a process involved in early formation of an organ in an embryo - known as a "developmental pathway" - is "hijacked." This causes production of an enzyme called DNMT3B much later during development, and in excessive quantities.
According to the researchers, forms of this enzyme have previously been found in some types of leukemia and breast cancers - and the enzyme is commonly linked to poor outcomes. Furthermore, DNMT3B has previously been linked to many cognitive problems.
The researchers discovered that patients with ETMR/ETANTR had DNMT3B in very large quantities, and also at a point of development when the enzyme should not be present at all.
The investigators say their findings suggest that DNMT3B could be a potential target for future therapies to treat ETMR/ETANTR, and the next steps will be to determine whether enzyme production can be controlled in the tumor and whether this could halt its growth.
Commenting on the study, co-principal investigator Dr. Nada Jabado, hemato-oncologist at the Montreal Children's Hospital of the MUHC and an associate professor in the Department of Pediatrics at McGill University, says:
"We undertook this study because we wanted to learn what was driving the growth of these tumors and how best to treat them.
This is a very aggressive disease with poor outcomes for patients; we urgently need better treatments for these kids, and this study, which helps us better understand what happens in this tumor, moves us a little closer to that target."
Dr. Annie Huang, a brain tumor specialist at SickKids, led a research group in 2009 that initially discovered that several forms of deadly brain tumors in young children were actually ETMR/ETANTR.
She says that the collaborations in this most recent study have "provided opportunities to take our initial discovery of this entity closer to finding innovative treatments for this disease, which we believe is an important, yet under-recognized, infantile brain tumor."
Written by Honor Whiteman
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR, doi:10.1038/ng.2849, Claudia L Kleinman, Noha Gerges, Simon Papillon-Cavanagh, Patrick Sin-Chan, Albena Pramatarova, Dong-Anh Khuong Quang, Véronique Adoue, Stephan Busche, Maxime Caron, Haig Djambazian, Amandine Bemmo, Adam M Fontebasso, Tara Spence, Jeremy Schwartzentruber, Steffen Albrecht, Peter Hauser, Miklos Garami, Almos Klekner, Laszlo Bognar, Jose-Luis Montes, Alfredo Staffa, Alexandre Montpetit, Pierre Berube, Magdalena Zakrzewska, Krzysztof Zakrzewski, et al., published in Nature Genetics, 8 December 2013. Abstract
Canadian researchers lead groundbreaking discovery in deadly childhood, news release from McGill University Health Centre, accessed 16 December 2013.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Whiteman, Honor. "'Breakthrough' may lead to new treatment for fatal childhood cancer." Medical News Today. MediLexicon, Intl., 17 Dec. 2013. Web.
12 Mar. 2014. <http://www.medicalnewstoday.com/articles/270254>
Whiteman, H. (2013, December 17). "'Breakthrough' may lead to new treatment for fatal childhood cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/270254.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.